List of Antibodies Companies in Sweden - 28

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.

Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.

Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

ArgusEye provides innovative sensor systems based on nanoplasmonic detection for real-time monitoring of biological systems and processes.

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Bionamic was founded by researchers to address the frustrating challenge of implementing digitalization in biopharma R&D. Our software platform can serve as a single source of truth for all your antibody related discovery and development data and offers an easy way to navigate it. We have put an incredible amount of thought and effort into making sure the data can be represented in a way that makes sense and helps to solve real problems.

Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.

Diaprost is a private pharmaceutical research and development company based in Lund, Sweden. The company's principal asset is hu5A10, a novel Theranostic Antibody licensed for development in the treatment and diagnosis of prostate cancer. Diaprost has also announced promising new studies for patients with metastatic prostate cancer, and has entered into license agreements with other companies for the development of its products.

Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymes™ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATOR™, FabALACTICA™, GingisKHAN™, FabULOUS™ & FabRICATOR Z™ General proteolysis - GingisREX™ De-glycosylation and conjugation of IgGs - GlycINATOR™, IgGZERO™ and GlyCLICK™ O-glycan analysis - OglyZOR™, OpeRATOR™, GlycOCATCH™ and SialEXO™

Gyros Protein Technologies provides enabling peptide synthesis and bioanalytical solutions helping scientists increase biomolecule performance and productivity in pre-clinical/clinical development and bioprocess applications. The automat

Hansa Biopharma, is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative and life altering treatments for patients with rare immunological conditions. Hansa scientists are working on developing immunomodulatory treatments for organ transplants, rare IgG-mediated autoimmune conditions, and gene therapy, as well as exploring the potential application of the technology platform in oncology.

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

We focus on development, modification and production of custom antibodies, as well as their antigens; typically synthetic peptides and recombinant proteins. With more than two decades of experience of delivering products and services in the field of molecular biology, we have a complete toolbox of taking a project from idea to finished antibody – and beyond.

Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products' development and manufacturing. 15,000 sq. m. Kemwell facility consists of a cGMP drug substance manufacturing area with over 4500L bioreactor capacity, sterile fill and finish areas for cGMP drug product manufacturing and process development laboratories to support production of protein therapeutics from mammalian-cell culture – monoclonal antibodies, bi-specific antibodies, fusion proteins, etc. Kemwell is capable of supporting novel, bio-better and biosimilar programs' preclinical development, clinical development, cGMP clinical manufacturing and cGMP commercial manufacturing. Kemwell, having established in 1980, had long term associations with pharma majors such as Bayer, GlaxoSmithKline, Merck KGaA, Novartis, Pfizer and others for small molecule contract mfg. and R&D. In 2016, Kemwell divested its small-molecule division to focus on biologics, leveraging its vast and rich experience. Kemwell is now a 100% biologics CDMO.

Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs.

LOKON PHARMA is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer-based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

We are a Swedish company developing immunoassays for life science research. Our goal is to aid research by providing the scientific community with innovative tools, in particular for ELISpot, FluoroSpot, and ELISA. To that end, we develop and produce a wide range of monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications. We started off in Stockholm in 1986, and our headquarters still lies in Nacka Strand, just east of the inner city. We do everything here, from research and production to finance, IT, quality control, marketing, distribution, and sales. In addition, we have a sales office in Cincinnati, Ohio, and collaborate with great distributors around the globe. The quality of our products really comes down to our entire organization; the balance between individual action and care for the collective. Because for us, quality isn't just a word. It's a mindset, a mantra, and a lens we hold to all our initiatives, whatever the size. As part of the scientific community, we want to do our share to help science progress. So we hope you see us as peers – feel free to strike up any sort of conversation with us.

Navinci is a Swedish biotech company that specializes in developing innovative solutions for the study of protein interactions. With a focus and a strong legacy in the development of in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth. Our Naveni Proximity Ligation Technology is at the forefront of innovation within the field of spatial proteomics and allows for the detection and quantification of protein interactions and post-translational modifications in a manner that is both sensitive and specific. It provides researchers with a valuable tool for their studies and helps deepen the understanding of the interplay between proteins in their native environment. Our latest focus is on target-specific kits within immuno-oncology, which detect interactions such as PD1/PD-L1. These kits are designed to help researchers easily visualize the interactions between immune checkpoint proteins in immune and cancer cells and elucidate the role that interactions, rather than individual proteins, play in the development of cancer. By providing researchers with reliable and innovative tools for visualizing and interpreting protein interplay, Navinci pushes forward the understanding of cell biology and brings precision to spatial proteomics.

Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses Abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.

Single cell spatial proteomics. Molecular Pixelation uses DNA-conjugated antibodies and DNA encoded pixels to identify and spatially locate cell surface proteins.

SARomics Biostructures provides a broad range of structural biology and drug discovery services that include: X-ray crystallography services: Protein cloning, expression, characterization, and crystallization, FastLane™ Standard and FastLane™ Premium off-the-shelf structures, gene-to-structure services. Protein NMR spectroscopy: Peptide NMR & protein NMR assignment, peptide NMR & protein NMR structure determination, protein-ligand & protein-protein complex structure determination, fragment screening using 1D or 2D NMR spectroscopy, epitope mapping and dissociation constant (Kd) determinations for compounds, biosimilars higher order structure (HOS) verification & comparability analysis, formulation characterization and optimization, expression and purification of 2H, 15N, and 13C-labelled protein in E.coli for NMR spectroscopy studies and structure determination. Structure-based lead discovery services: Fragment screening and fragment-based drug design, computational chemistry, in silico drug discovery services. Our integrated drug discovery platform relies on our unique and proprietary weak affinity chromatography screening technology (WAC™). Antibody & antibody-antigen 3D structure determination, higher order structure (HOS) comparability analysis of biosimilars. Why choose SARomics Biostructures The commitments of our highly experienced and competent team of crystallographers, modelers, and molecular biologists include: Swift replies to all contact requests. After the initial project discussion, we provide realistic project timelines. We guarantee high quality services. We have a high degree of customer satisfaction. Our robust technology platform is built around a wide variety of experimental methods required in modern structural biology. We use a unique and verified proprietary method for compound screening. We benefit from an excellent location in Medicon Village in Lund and proximity to one of the world's best synchrotrons, MAX IV.

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2023, our revenue amounted to SEK 22.1 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

For customers working in the life sciences and pharma industry, Svar offers a unique combination of scientific expertise, high-quality assay products, strong services, and proprietary technology platforms that provide a flexible, effective, and seamless experience for customers through different development needs in a way that no other single business can. At Svar, we are dedicated to our customers' development journey. We harness a deep understanding and long-standing experience in immunological areas such as complement system activation and immunogenicity. We utilize this in our expert cell engineering, assay development, and contract research services capabilities. Our specialist knowledge allows us to help you tackle complex problems, safely and efficiently moving your candidates through the drug development phases and to the patient—also when standard solutions fall short.

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2022, our revenue amounted to SEK 18.8 billion.

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.